The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Radiotherapy (RT), temozolomide (TMZ), procarbazine (PCB), and the integrin inhibitor cilengitide in patients (pts) with glioblastoma (GBM) without methylation of the MGMT gene promoter (ExCentric): Results of an Australian phase II clinical trial.
Mustafa Khasraw
Research Funding - Merck Serono
Sally Anne McCowatt
No relevant relationships to disclose
Marc E. Buyse
No relevant relationships to disclose
Zoltan Kerstes
No relevant relationships to disclose
Michael Back
Consultant or Advisory Role - Merck Sharp & Dohme
Ganessan Kichenadasse
No relevant relationships to disclose
Helen Wheeler
Research Funding - Merck Serono